CX Institutional Boosts Stock Position in Cencora, Inc. $COR

CX Institutional increased its position in Cencora, Inc. (NYSE:COR) by 28.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,069 shares of the company’s stock after acquiring an additional 6,030 shares during the quarter. CX Institutional’s holdings in Cencora were worth $7,660,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kemnay Advisory Services Inc. bought a new position in shares of Cencora in the fourth quarter worth approximately $25,000. Oakworth Capital Inc. purchased a new stake in shares of Cencora in the fourth quarter worth $26,000. Elyxium Wealth LLC bought a new stake in shares of Cencora during the 4th quarter valued at $27,000. Archer Investment Corp raised its position in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after purchasing an additional 47 shares during the period. Finally, Motiv8 Investments LLC purchased a new position in shares of Cencora during the 4th quarter valued at $29,000. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on COR. Bank of America upped their target price on shares of Cencora from $280.00 to $285.00 and gave the stock a “neutral” rating in a report on Wednesday, June 24th. William Blair began coverage on Cencora in a report on Tuesday, April 28th. They set a “market perform” rating on the stock. Wells Fargo & Company lowered their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. UBS Group upped their price objective on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, Citigroup cut their target price on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $367.75.

Cencora Price Performance

Shares of NYSE:COR opened at $308.21 on Tuesday. The firm has a market cap of $59.97 billion, a price-to-earnings ratio of 23.64, a P/E/G ratio of 1.73 and a beta of 0.57. The firm has a fifty day moving average price of $290.02 and a 200 day moving average price of $315.15. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 17.8 earnings per share for the current fiscal year.

Cencora declared that its Board of Directors has approved a share repurchase plan on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to repurchase up to 3.9% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Cencora

In other news, Director Lauren M. Tyler acquired 550 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was purchased at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the transaction, the director directly owned 4,359 shares in the company, valued at approximately $1,177,932.57. This trade represents a 14.44% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.38% of the stock is currently owned by insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.